CHANT (Cerebral Hemorrhage And NXY Treatment) A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter, Phase IIb Study to Assess the Safety and Tolerability of Intravenous Infusion of NXY-059 in Adult Patients With Acute Intracerebral Hemorrhage (ICH)

Fecha de inicio: 1 de agosto de 2004

Inclusion Criteria: * Males and females * Intracerebral Hemorrhage as the cause of stroke symptoms * Onset of symptoms within 6 hours * Full functional independence prior to the present stroke Exclusion Criteria: * Unconsciousness * Subjects who are unlikely to complete the infusion of investigational product and/or are unlikely to undergo active medical management during that period due to a severe clinical condition. * Severe illness with life expectancy less than 6 months. * Known severe kidney disorder. * Current known alcohol or illicit drug abuse or dependence. * Pregnant or breast-feeding. * Treatment with acetazolamide and methotrexate is not permitted during the infusion * Participation in a previous clinical study within 7 days. * Meets all other exclusion criteria